Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions 2025, hosted by the American Heart Association in New Orleans from 8th –10th November.
Representing Richmond at the AHA 2025:
Dr Jörg Täubel, Chief Executive Officer
James Rickard, Chief Scientific Officer
We look forward to connecting with attendees to discuss Richmond’s expertise in:
• Early-phase cardiovascular and cardiometabolic research
• First-in-human and dose-ranging studies
• Novel biomarkers and digital endpoints
• Regulatory engagement and global trial delivery
• Patient-first strategies in complex CV trials
If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us: info@richmondpharmacology.com
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Richmond Pharmacology will attend BioJapan 2025 in Yokohama, represented by their leadership team. The event focuses on early-phase trials, UK–Japan collaboration, regulatory strategy, bridging studies, and adaptive trial models.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
-min.jpg)
.jpg)
